ArticleJournal of thoracic disease2026
The hemodynamic and clinical characteristics of recurrent hemoptysis in bronchiectasis patients after vascular intervention procedures.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchial artery embolization (BAE) is an established treatment for hemoptysis in bronchiectasis, yet the risk of post-procedural recurrence remains significant. This study aimed to investigate the clinical and hemodynamic predictors of hemoptysis recurrence in patients with bronchiectasis following BAE. Methods: We retrospectively analyzed 426 patients with bronchiectasis-related hemoptysis who underwent BAE between 2019 and 2022. Patients were followed for a median of 2 years to monitor recurrence. Baseline clinical data, angiographic findings, and hemodynamic parameters obtained via right heart catheterization were compared between recurrence and non-recurrence groups. Multivariate Cox proportional hazards regression was employed to identify independent risk factors for recurrence. Results: Among the 426 patients, 113 (26.53%) experienced recurrence during the follow-up period. The recurrence group exhibited more severe imaging findings, including a higher prevalence of multilobar involvement (≥3 lobes: 47.79% Conclusions: BAE is an effective intervention for hemoptysis in bronchiectasis, but recurrence is common. The presence of SPS and elevated TPR are key independent risk factors for post-BAE recurrence, highlighting the importance of hemodynamic assessment in predicting long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.